Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 657.8 Million EUR | -22.78% |
| 2022 | 851.7 Million USD | 30.63% |
| 2021 | 651.97 Million EUR | -14.99% |
| 2020 | 766.92 Million EUR | 13.68% |
| 2019 | 674.62 Million EUR | 17.8% |
| 2018 | 572.7 Million EUR | -4.44% |
| 2017 | 599.29 Million EUR | -5.46% |
| 2016 | 633.9 Million EUR | -0.96% |
| 2015 | 640.04 Million EUR | 4.31% |
| 2014 | 613.6 Million EUR | 0.03% |
| 2013 | 613.4 Million EUR | -2.56% |
| 2012 | 629.5 Million EUR | 2.73% |
| 2011 | 612.8 Million EUR | 8.13% |
| 2010 | 566.7 Million EUR | 11.93% |
| 2009 | 506.3 Million EUR | 8.35% |
| 2008 | 467.3 Million EUR | 1.43% |
| 2007 | 460.7 Million EUR | 123.64% |
| 2006 | 206 Million EUR | -62.01% |
| 2005 | 542.3 Million EUR | 5.08% |
| 2004 | 516.1 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 184.29 Million EUR | -3.39% |
| 2024 Q2 | 189.2 Million EUR | 10.36% |
| 2024 Q3 | 319.4 Million EUR | 69.44% |
| 2023 Q1 | 171.45 Million USD | 3.22% |
| 2023 FY | 657.7 Million EUR | -22.78% |
| 2023 Q4 | 195.14 Million EUR | 7.64% |
| 2023 Q3 | 181.29 Million USD | 8.56% |
| 2023 Q2 | 166.99 Million USD | -2.6% |
| 2022 Q3 | 348.59 Million EUR | 91.72% |
| 2022 FY | 851.7 Million USD | 30.63% |
| 2022 Q2 | 181.82 Million EUR | 10.53% |
| 2022 Q4 | 166.1 Million USD | -52.35% |
| 2022 Q1 | 164.5 Million EUR | 7.1% |
| 2021 Q4 | 153.6 Million EUR | 17.61% |
| 2021 Q1 | 180.99 Million EUR | 29.47% |
| 2021 Q2 | 184.17 Million EUR | 1.75% |
| 2021 Q3 | 130.6 Million EUR | -29.09% |
| 2021 FY | 651.97 Million EUR | -14.99% |
| 2020 Q3 | 143.5 Million EUR | -24.11% |
| 2020 Q1 | 173.4 Million EUR | 7.37% |
| 2020 Q2 | 189.1 Million EUR | 9.05% |
| 2020 FY | 766.92 Million EUR | 13.68% |
| 2020 Q4 | 139.8 Million EUR | -2.58% |
| 2019 Q2 | 150.2 Million EUR | 4.02% |
| 2019 Q1 | 144.4 Million EUR | -10.42% |
| 2019 FY | 674.62 Million EUR | 17.8% |
| 2019 Q4 | 161.5 Million EUR | -8.81% |
| 2019 Q3 | 177.1 Million EUR | 17.91% |
| 2018 FY | 572.7 Million EUR | -4.44% |
| 2018 Q4 | 161.2 Million EUR | 31.48% |
| 2018 Q3 | 122.6 Million EUR | -21.51% |
| 2018 Q2 | 156.2 Million EUR | 4.48% |
| 2018 Q1 | 149.5 Million EUR | -11.38% |
| 2017 Q4 | 168.7 Million EUR | 30.27% |
| 2017 Q3 | 129.5 Million EUR | -17.93% |
| 2017 Q2 | 157.8 Million EUR | -5.96% |
| 2017 Q1 | 167.8 Million EUR | 0.66% |
| 2017 FY | 599.29 Million EUR | -5.46% |
| 2016 Q3 | 151.8 Million EUR | -12.61% |
| 2016 Q4 | 166.7 Million EUR | 9.82% |
| 2016 Q1 | 159.8 Million EUR | 8.71% |
| 2016 Q2 | 173.7 Million EUR | 8.7% |
| 2016 FY | 633.9 Million EUR | -0.96% |
| 2015 Q3 | 133.8 Million EUR | -16.64% |
| 2015 FY | 640.04 Million EUR | 4.31% |
| 2015 Q4 | 147 Million EUR | 9.87% |
| 2015 Q2 | 160.5 Million EUR | -4.75% |
| 2015 Q1 | 168.5 Million EUR | 13.01% |
| 2014 Q3 | 138.2 Million EUR | -21.96% |
| 2014 Q1 | 149.2 Million EUR | -10.12% |
| 2014 Q4 | 149.1 Million EUR | 7.89% |
| 2014 FY | 613.6 Million EUR | 0.03% |
| 2014 Q2 | 177.1 Million EUR | 18.7% |
| 2013 Q1 | 157.5 Million EUR | -0.32% |
| 2013 FY | 613.4 Million EUR | -2.56% |
| 2013 Q2 | 149.2 Million EUR | -5.27% |
| 2013 Q4 | 166 Million EUR | 18.07% |
| 2013 Q3 | 140.6 Million EUR | -5.76% |
| 2012 FY | 629.5 Million EUR | 2.73% |
| 2012 Q1 | 160.6 Million EUR | 6.5% |
| 2012 Q4 | 158 Million EUR | -1.5% |
| 2012 Q3 | 160.4 Million EUR | 6.51% |
| 2012 Q2 | 150.6 Million EUR | -6.23% |
| 2011 Q1 | 171.4 Million EUR | 21.47% |
| 2011 Q3 | 138.3 Million EUR | -9.13% |
| 2011 Q4 | 150.8 Million EUR | 9.04% |
| 2011 FY | 612.8 Million EUR | 8.13% |
| 2011 Q2 | 152.2 Million EUR | -11.2% |
| 2010 Q3 | 141.6 Million EUR | 1.72% |
| 2010 Q4 | 141.1 Million EUR | -0.35% |
| 2010 Q1 | 144.8 Million EUR | 16.59% |
| 2010 FY | 566.7 Million EUR | 11.93% |
| 2010 Q2 | 139.2 Million EUR | -3.87% |
| 2009 Q2 | 128.3 Million EUR | 0.0% |
| 2009 FY | 506.3 Million EUR | 8.35% |
| 2009 Q4 | 124.2 Million EUR | -1.04% |
| 2009 Q3 | 125.5 Million EUR | -2.18% |
| 2009 Q1 | 128.3 Million EUR | 0.0% |
| 2008 FY | 467.3 Million EUR | 1.43% |
| 2007 FY | 460.7 Million EUR | 123.64% |
| 2006 FY | 206 Million EUR | -62.01% |
| 2005 FY | 542.3 Million EUR | 5.08% |
| 2004 FY | 516.1 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 98.104% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 98.083% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 97.817% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -5753.876% |
| Novartis AG | 34.18 Billion USD | 98.076% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | 11.523% |